- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00918983
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
April 1, 2014 updated by: Nymox Corporation
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
500
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- For information concerning this clinical site, please contact Nymox at 800-936-9669
-
Huntsville, Alabama, United States, 35801
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Arizona
-
Tucson, Arizona, United States, 85712
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
California
-
Anaheim, California, United States, 92801
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Atherton, California, United States, 94027
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
La Mesa, California, United States, 91942
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Long Beach, California, United States, 90806
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Los Alamitos, California, United States, 90720
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Colorado
-
Denver, Colorado, United States, 80211
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Connecticut
-
New Britain, Connecticut, United States, 06052
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Florida
-
Naples, Florida, United States, 34102
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Ocala, Florida, United States, 34474
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Orlando, Florida, United States, 32806
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Tallahassee, Florida, United States, 32308
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- For information concerning this clinical site, please contact Nymox at 800-936-9669
-
Roswell, Georgia, United States, 30076
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Indiana
-
Jeffersonville, Indiana, United States, 47130
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Newburg, Indiana, United States, 47630
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71106
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Montana
-
Missoula, Montana, United States, 59802
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
New Jersey
-
Lawrenceville, New Jersey, United States, 08648
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Mt. Laurel, New Jersey, United States, 08054
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Voorhees, New Jersey, United States, 08043
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
New York
-
Brooklyn, New York, United States, 11215
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Garden City, New York, United States, 11530
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Poughkeepsie, New York, United States, 12601
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
North Carolina
-
Concord, North Carolina, United States, 28025
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Raleigh, North Carolina, United States, 27607
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Ohio
-
Cincinnati, Ohio, United States, 45212
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Columbus, Ohio, United States, 43221
- For information concerning this clinical site, please contact Nymox at 800-936-9669
-
-
Oklahoma
-
Bethany, Oklahoma, United States, 73008
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Oregon
-
Salem, Oregon, United States, 97301
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Pennsylvania
-
Bala Cynwyd, Pennsylvania, United States, 19004
- For information concerning this clinical site, please contact Nymox at 800-936-9669
-
Lancaster, Pennsylvania, United States, 17604
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
South Carolina
-
Myrtle Beach, South Carolina, United States, 29572
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Texas
-
Arlington, Texas, United States, 76017
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Carrollton, Texas, United States, 75010
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
Dallas, Texas, United States, 75231
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- For information concerning this clinical site, please contact Nymox at 800-936-9669.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Provide signed informed consent prior to enrolment in the study
- IPSS ≥ 15
- Prostate Volume ≥ 30 mL ≤ 70 mL
- Qmax < 15 mL/sec based on a minimum void of 125 mL
- Agree not to use any other approved or experimental BPH or OAB medication anytime during the study
Exclusion Criteria:
- History of illness or condition that may interfere with study or endanger subject
- Use of prescribed medications that may interfere with study or endanger subject
- Presence of a median lobe of the prostate
- Previous surgery or MIST for treatment of BPH
- Post-void residual urine volume > 200 mL
- PSA ≥ 10 ng/mL; prostate cancer must be ruled out (negative biopsy) for PSA ≥ 4 ng/mL
- Participation in a study of any investigational drug or device within the previous 90 days
- Prostate cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Single intraprostatic injection of placebo
|
Experimental: NX-1207
|
Single intraprostatic injection of 2.5 mg NX-1207
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
International Prostate Symptom Score (IPSS)
Time Frame: 365 days
|
365 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
International Prostate Symptom Score (IPSS)
Time Frame: 90 days
|
90 days
|
International Prostate Symptom Score (IPSS)
Time Frame: 180 days
|
180 days
|
International Prostate Symptom Score (IPSS)
Time Frame: 270 days
|
270 days
|
Peak urine flow rate (Qmax)
Time Frame: 365 days
|
365 days
|
Peak urine flow rate (Qmax)
Time Frame: 90 days
|
90 days
|
Peak urine flow rate (Qmax)
Time Frame: 180 days
|
180 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (Actual)
November 1, 2013
Study Completion (Actual)
November 1, 2013
Study Registration Dates
First Submitted
June 9, 2009
First Submitted That Met QC Criteria
June 10, 2009
First Posted (Estimate)
June 11, 2009
Study Record Updates
Last Update Posted (Estimate)
April 30, 2014
Last Update Submitted That Met QC Criteria
April 1, 2014
Last Verified
April 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NX02-0017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
San Carlo di Nancy HospitalElesta S.R.L.CompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy | Benign Prostatic Hypertrophy With Outflow Obstruction | Prostate HyperplasiaItaly
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
Catholic University of the Sacred HeartCompletedBenign Prostatic Hyperplasia (BPH) | Benign Prostatic Enlargement (BPE)Italy
-
Boston Scientific CorporationCompletedProstatic Hyperplasia | Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic, Czechia, Sweden
-
Boston Scientific CorporationCompletedBenign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic
-
IMBiotechnologies Ltd.CompletedBenign Prostatic Hyperplasia | Benign Prostatic HypertrophyCanada
-
IRCCS Policlinico S. MatteoCompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy With Outflow ObstructionItaly
-
American Medical SystemsCompletedBenign Prostatic Hyperplasia | BPH | Benign Prostatic Hypertrophy | Prostate Disease
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingLower Urinary Tract Symptoms | Benign Prostate Hyperplasia | Benign Prostatic Hypertrophy With Outflow Obstruction
Clinical Trials on NX-1207
-
Nymox CorporationCompletedProstate CancerUnited States
-
Nymox CorporationCompletedBenign Prostatic Hyperplasia | BPH | LUTS | Lower Urinary Tract Symptoms (LUTS)United States
-
Nymox CorporationCompletedBenign Prostatic HyperplasiaUnited States
-
Nymox CorporationCompletedBenign Prostatic Hyperplasia (BPH)United States
-
Nymox CorporationCompletedPhase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)Benign Prostatic Hyperplasia (BPH) | Enlarged ProstateUnited States
-
Jeil Pharmaceutical Co., Ltd.CompletedOveractive Bladder | Benign Prostatic Hyperplasia | LUTS
-
Landos Biopharma Inc.RecruitingUlcerative ColitisUnited States, Belgium, Italy, Poland
-
Landos Biopharma Inc.CompletedUlcerative ColitisUnited States, Ukraine
-
Lava TherapeuticsRecruitingMetastatic Castration Resistant Prostate CancerUnited States
-
Abbisko Therapeutics Co, LtdRecruitingSolid TumorUnited States, China